Surrogacy Case Study: Prostate Specific Antigen (PSA ... - Isped

More documents

Recommendations

Info

Treatment effects on OS against treatment effects on Time to <strong>PSA</strong> Progression (20% rise) Effect on survival (log HR) 1.0 -0.5 0.0 0.5 1.0 1.5 -1.0 2.0 -2.0 -3.0 -4.0 R 2 trial = 0.21 (CI: 0 – 0.56) Low trial-unit correlation -5.0 Effect on TTPP-1 (log HR) Within patient: concordance coefficient τ = 0.52 (SE=0.004)
Treatment effects on OS against treatment effects on Time to <strong>PSA</strong> Progression (50% rise) -0.5 Effect on survival (log HR) -0.5 0.0 0.5 1.0 -0.5 R 2 trial = 0.66 (CI: 0.3 – 0.85) Moderate trial-unit correlation Effect on TTPP-2 (log HR) Within patient: concordance coefficient τ = 0.61 (SE=0.02)
Page 1 and 2: EORTC Surrogacy Case Study: Prostat
Page 3 and 4: Prostate Specific Antigen (PSA) •
Page 5 and 6: Transition between clinical states
Page 7 and 8: Surrogate endpoint • An outcome m
Page 9 and 10: Meta-analytic validation First stag
Page 11 and 12: PSA - defined endpoints in prostate
Page 13 and 14: PSA “surrogacy” studies in the
Page 15 and 16: Published PSA surrogacy studies Col
Page 17 and 18: Review • 2 meta-analytic validati
Page 19 and 20: PSA endpoints PSA normalization A P
Page 21: PSA data (M1) Mean log(PSA) -2 0 2
Page 25 and 26: Prediction for a new trial - M1 •
Page 27 and 28: PSA doubling-free survival (PSA-D)
Page 29 and 30: Recommendation, M1 hormone sensitiv
Page 31 and 32: 4m vs 24m ADT adjuvant to irradiati
Page 33 and 34: PSA-DT and TTBF surrogate for PCa-s
Page 35 and 36: PSA response or PSA-V surrogate for
Page 37 and 38: Of interest… The search for the g
Page 39 and 40: Conclusions for HRPC on chemotherap
Page 41 and 42: ASCENT trial High dose Calcitriol (
Page 43 and 44: Be aware of your drug’s effect on

Surrogacy Case Study: Prostate Specific Antigen (PSA ... - Isped

Create successful ePaper yourself

Delete template?

Save as template?